WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 555243
CAS#: 1804915-68-1 (sodium)
Description: WCK-4234 is a potent β-lactamase inhibitor. WCK-4234 inhibited class A, C and D β-lactamases with unprecedented k2/K values against OXA carbapenemases. WCK-4234 inhibited class A, C and D β-lactamases with unprecedented k2/K values against OXA carbapenemases. WCK-4234 formed highly stable acyl-complexes via mass spectrometry. WCK-4234 is a novel β-lactamase inhibitor that demonstate potent cross-class inhibition and clinical studies targeting MDR infections are warranted.
MedKoo Cat#: 555243
Name: WCK-4234 sodium
CAS#: 1804915-68-1 (sodium)
Chemical Formula: C7H8N3NaO5S
Molecular Weight: 269.2068
Elemental Analysis: C, 31.23; H, 3.00; N, 15.61; Na, 8.54; O, 29.72; S, 11.91
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 1804915-68-1 (sodium) 1706523-58-1 (free acid)
Synonym: WCK-4234; WCK 4234; WCK4234.
IUPAC/Chemical Name: sodium (2S,5R)-2-cyano-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl sulfate
InChi Key: RYJWKSOILDDAHI-RIHPBJNCSA-M
InChi Code: InChI=1S/C7H9N3O5S.Na/c8-3-5-1-2-6-4-9(5)7(11)10(6)15-16(12,13)14;/h5-6H,1-2,4H2,(H,12,13,14);/q;+1/p-1/t5-,6+;/m0./s1
SMILES Code: O=S(ON1[C@]2([H])CC[C@@H](C#N)N(C2)C1=O)([O-])=O.[Na+]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 269.2068 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Papp-Wallace KM, Nguyen NQ, Jacobs MR, Bethel CR, Barnes MD, Kumar V,
Bajaksouzian S, Rudin SD, Rather PN, Bhavsar S, Ravikumar T, Deshpande PK, Patil
V, Yeole R, Bhagwat SS, Patel MV, van den Akker F, Bonomo RA. Strategic
approaches to overcome resistance against Gram negative pathogens using
β-lactamase inhibitors and β-lactam enhancers: The activity of three novel
diazabicyclooctanes, WCK 5153, zidebactam (WCK 5107), and WCK 4234. J Med Chem.
2018 Apr 7. doi: 10.1021/acs.jmedchem.8b00091. [Epub ahead of print] PubMed PMID:
2: Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Papp-Wallace KM, Bonomo RA,
Oliver A. Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against
Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.
Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01238-17. doi:
10.1128/AAC.01238-17. Print 2017 Nov. PubMed PMID: 28848013; PubMed Central
3: Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Papp-Wallace KM, Bonomo RA,
Oliver A. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing
Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including
Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones. Antimicrob
Agents Chemother. 2017 May 24;61(6). pii: e02529-16. doi: 10.1128/AAC.02529-16.
Print 2017 Jun. PubMed PMID: 28289035; PubMed Central PMCID: PMC5444176.
Limited treatment options exist to combat infections caused by multidrug-resistant (MDR) Gram negative bacteria possessing broad-spectrum β-lactamases.